oral
administr
major
drug
molecul
absorb
across
small
intestin
enter
system
circul
via
portal
vein
liver
highli
lipophil
drug
typic
log
p
n
lipid
solubl
n
mgg
howev
associ
lymph
lipoprotein
enterocyt
lead
transport
system
circul
via
intestin
lymph
attend
deliveri
benefit
associ
lymphat
drug
transport
includ
reduct
firstpass
metabol
lymphat
exposur
drug
concentr
order
magnitud
higher
attain
system
blood
current
review
briefli
describ
mechan
drug
molecul
access
lymph
formul
strategi
may
utilis
enhanc
lymphat
drug
transport
specif
focu
direct
toward
recent
advanc
understand
regard
impact
lipid
sourc
endogen
exogen
intracellular
lipid
traffick
pathway
lymphat
drug
transport
enterocytebas
firstpass
metabol
becom
evid
pressur
identifi
increasingli
potent
lead
compound
lead
identif
increasingli
lipophil
drug
candid
respons
describ
throughout
theme
issu
grow
number
formul
technolog
develop
support
absorpt
compound
low
water
solubl
high
lipophil
combin
factor
led
common
confid
preclin
clinic
progress
compound
physicochem
characterist
consist
potenti
lymphat
transport
typic
log
p
n
long
chain
triglycerid
tg
solubl
n
mgg
understand
mechan
drug
access
intestin
lymph
potenti
ramif
drug
transport
system
circul
via
intestin
lymph
rather
portal
blood
impact
formul
chang
intestin
lymphat
transport
signific
much
broader
audienc
area
intestin
lymphat
transport
review
other
recent
year
aim
current
articl
therefor
revisit
detail
mani
gener
aspect
well
cover
previous
rather
focu
recent
advanc
understand
mechan
drug
access
intestin
lymph
import
enterocytebas
lipid
process
determin
pattern
lymphat
drug
transport
basic
principl
dictat
mechan
drug
enter
intestin
lymph
follow
oral
deliveri
summaris
fig
gastrointestin
tract
richli
suppli
lymphat
blood
vessel
therefor
materi
absorb
across
small
intestin
epitheli
cell
enterocyt
potenti
enter
either
lymphat
blood
capillari
major
absorb
materi
transport
portal
blood
rate
fluid
flow
portal
blood
approxim
higher
intestin
lymph
howev
facil
diffus
across
blood
capillari
endothelium
limit
exampl
high
molecular
weight
colloid
materi
select
transport
intestin
lymph
may
occur
sinc
endotheli
architectur
lymphat
dictat
lymphat
capillari
significantli
permeabl
neighbour
blood
capillari
absorpt
macromolecular
drug
construct
across
enterocyt
howev
limit
drug
access
intestin
lymph
commonli
occur
result
postabsorpt
associ
colloid
lipoprotein
transport
across
enterocyt
see
fig
physic
size
lipoprotein
subsequ
dictat
diffus
across
vascular
endothelium
limit
preferenti
access
lipoprotein
associ
drug
lymphat
occur
mechan
support
studi
demonstr
major
lymphat
transport
ddt
aryl
alkyl
hydrocarbon
halofantrin
solubilis
within
apolar
lipid
core
lymph
lipoprotein
lymphat
transport
shown
contributor
oral
bioavail
number
highli
lipophil
drug
xenobiot
follow
oral
deliveri
includ
two
lipophil
cannabinoid
halofantrin
moxidectin
mepitiostan
testosteron
deriv
inhibitor
penclomedin
naftifin
probucol
cyclosporin
ontazolast
fat
solubl
vitamin
deriv
retinoid
lycopen
ddt
analog
benzopyren
pcb
polychlorin
biphenyl
number
lipophil
prodrug
contrast
small
quantiti
hydrophil
drug
salicyl
acid
isoniazid
caffein
recov
lymph
follow
oral
deliveri
rate
flow
portal
blood
howev
higher
mesenter
lymph
drug
enter
portal
blood
avidli
mesenter
lymph
contrast
follow
uptak
enterocyt
fatti
acid
fa
monoglycerid
mg
digest
product
resynthesis
triglycerid
tg
assembl
colloid
lipoprotein
lp
within
endoplasm
reticulum
lp
exocytos
across
basolater
membran
enterocyt
preferenti
access
mesenter
lymph
vessel
size
preclud
easi
diffus
across
vascular
endothelium
highli
lipophil
drug
log
p
n
long
chain
tg
solubl
n
mgg
may
therefor
access
intestin
lymph
via
associ
develop
lipoprotein
enterocyt
properti
lipoprotein
rather
drug
dictat
lymphat
access
realis
drug
access
intestin
lymph
depend
drug
associ
develop
lipoprotein
enterocyt
suggest
provis
appropri
lipid
sourc
drive
lipoprotein
assembl
key
strategi
enhanc
lymphat
drug
transport
inde
effici
lipid
digest
solubilis
intestin
lumen
review
elsewher
issu
previous
subsequ
uptak
transport
across
intestin
absorpt
cell
like
significantli
influenc
access
lipophil
drug
lymph
type
mass
coadminist
lipid
alter
extent
lymphat
drug
transport
subject
well
review
previous
briefli
fatti
acid
fa
chain
length
greater
highli
lymphat
transport
lipid
dose
transport
system
circul
via
intestin
lymph
remaind
absorb
via
portal
vein
blood
wherea
shorter
chain
fa
water
solubl
primarili
absorb
via
portal
blood
long
chain
fa
triglycerid
tg
compos
long
chain
fa
effect
support
lymphat
drug
transport
medium
short
chain
counterpart
degre
unsatur
administ
fa
also
influenc
extent
lymphat
lipid
drug
transport
gener
monoand
polyunsatur
fa
mufa
pufa
respect
promot
lymphat
lipid
transport
readili
produc
larger
size
lipoprotein
therefor
enhanc
lymphat
drug
transport
effect
compar
equival
satur
fa
phospholipid
pl
particular
phosphatidylcholin
pc
digest
product
lysophosphatidylcholin
lpc
also
enhanc
lymphat
lipid
transport
lpc
shown
enhanc
lymphat
transport
recent
halofantrin
prodrug
approach
may
also
taken
enhanc
lymphat
drug
transport
via
coval
coupl
drug
lipid
moieti
includ
fatti
acid
diglycerid
phosphoglycerid
simpl
fatti
acid
ester
aim
enhanc
lipophil
therefor
drug
associ
lipoprotein
enterocyt
howev
instabl
ester
linkag
intestin
enterocyt
typic
result
rel
ineffici
lymphat
target
glycerid
phospholipidbas
prodrug
howev
design
mimic
intercal
glycerid
phospholipid
resynthet
pathway
within
enterocyt
typic
stabl
therefor
lead
enhanc
lymphat
recoveri
lymphdirect
prodrug
strategi
review
detail
elsewher
due
uniqu
anatomi
physiolog
lymphat
intestin
lymphat
drug
transport
provid
number
advantag
drug
absorpt
via
portal
blood
exampl
drug
absorb
via
intestin
lymphat
system
essenti
protect
hepat
firstpass
metabol
sinc
mesenter
lymph
contrast
portal
blood
enter
system
circul
directli
without
first
pass
liver
drug
highli
metabolis
first
pass
liver
transport
via
lymphat
system
therefor
significantli
enhanc
oral
bioavail
lymphat
system
also
principl
system
transport
pathway
b
lymphocyt
well
primari
rout
metastat
spread
number
solid
tumour
suggest
immunomodulatori
anticanc
compound
may
effect
absorb
via
lymphat
rout
recent
evid
suggest
lymph
lymphoid
tissu
particular
gut
associ
lymphoid
tissu
play
major
role
develop
human
immunodefici
viru
hiv
antivir
target
aid
may
therefor
effect
absorb
via
intestin
lymphat
inde
recent
commun
describ
synthesi
lipid
prodrug
didanosin
design
improv
treatment
hiv
virus
may
also
spread
via
lymphat
network
includ
hepat
b
morbilliviru
also
replic
gut
associ
lymphoid
tissu
close
relat
canin
distemp
viru
sever
acut
respiratori
syndrom
sar
associ
coronaviru
chronic
persist
hepat
c
believ
result
uptak
system
lymphocyt
sequestr
lymph
convers
drug
transport
via
intestin
lymph
result
alter
pattern
local
drug
exposur
lymphat
chang
mode
deliveri
system
circul
therefor
potenti
chang
toxicolog
profil
also
possibl
evalu
intestin
lymphat
drug
transport
requir
invas
larg
irrevers
surgeri
access
cannul
intestin
lymphat
duct
lymphat
drug
transport
studi
directli
human
variou
anim
model
therefor
describ
attempt
quantit
contribut
lymphat
system
overal
drug
absorpt
major
case
preclin
model
collect
entir
volum
lymph
flow
mesenter
thorac
lymph
duct
cannula
therefor
provid
absolut
indic
extent
lymphat
transport
model
also
examin
use
lymphoven
shunt
advantag
allow
sampl
lymph
much
longer
period
although
case
rel
small
databas
lymph
flow
rate
make
estim
absolut
extent
lymphat
transport
difficult
major
lymphat
transport
studi
describ
literatur
utilis
rat
reflect
rel
eas
sourc
hous
small
laboratori
anim
howev
larger
anim
model
dog
pig
sheep
rabbit
also
describ
advantag
larger
anim
model
includ
capac
dose
clinic
relev
fullsiz
human
dosag
form
abil
administ
compound
repres
fed
fast
state
rodent
eat
command
gastrointestin
tract
transit
profil
biliari
secret
pattern
dog
pig
also
similar
human
compar
rat
bile
continu
secret
intestin
howev
complex
cost
larger
anim
model
typic
limit
widespread
applic
recent
altern
vivo
approach
estim
intestin
lymphat
drug
transport
describ
system
exposur
drug
assess
drug
administr
presenc
absenc
inhibitor
intestin
chylomicron
flow
eg
colchicin
comparison
system
drug
exposur
profil
presenc
absenc
function
intestin
lymphat
system
provid
indic
import
otherwis
lymphat
drug
transport
overal
bioavail
approach
advantag
requir
surgic
intervent
inher
lymph
duct
cannul
howev
broader
implic
block
chylomicron
flow
intestin
lipid
process
drug
exposur
indirectli
lymphat
transport
yet
studi
detail
use
vitro
model
altern
vivo
model
assess
lymphat
drug
transport
also
describ
exampl
cell
well
recognis
pharmaceut
arena
vitro
model
intestin
epithelium
wide
utilis
screen
intestin
permeabl
properti
howev
cell
also
employ
lipid
biochemistri
literatur
examin
aspect
intracellular
lipoprotein
assembl
recent
evalu
prospect
vitro
model
examin
influenc
lipid
lipid
excipi
drug
incorpor
lipoprotein
lymphat
transport
data
review
detail
elsewher
theme
issu
gershkovich
hoffman
also
suggest
degre
ex
vivo
associ
drug
chylomicron
harvest
plasma
may
use
simpl
predict
tool
like
extent
lymphat
drug
transport
studi
reason
linear
correl
r
obtain
extent
lymphat
transport
sever
lipophil
drug
degre
associ
plasma
chylomicron
ex
vivo
importantli
correl
substanti
better
extent
lymphat
drug
transport
tg
solubl
log
p
silico
method
aim
develop
quantit
relationship
molecular
structur
extent
intestin
lymphat
drug
transfer
also
recent
describ
author
found
rel
complex
set
molecular
descriptor
requir
predict
likelihood
lymphat
transport
although
approach
appear
give
accur
predict
obtain
use
tradit
descriptor
log
p
tg
solubl
number
lipid
transport
protein
identifi
apic
basolater
membran
enterocyt
togeth
sever
famili
intracellular
lipid
bind
protein
facilit
absorpt
intracellular
transport
endogen
dietari
lipid
transport
bind
protein
review
detail
elsewher
fig
depict
schemat
summaris
lipid
transport
bind
protein
implic
uptak
transport
variou
lipid
across
intestin
epitheli
cell
briefli
lipid
uptak
across
apic
membran
enterocyt
may
proceed
either
activ
transport
passiv
diffus
number
transport
implic
apic
membran
uptak
fa
eg
scaveng
receptor
bi
srbi
fabp
pm
cholesterol
eg
srbi
caveolin
aminopeptidas
n
although
rel
contribut
protein
inde
role
passiv
vs
activ
uptak
overal
intestin
absorpt
lipid
yet
fulli
resolv
apic
membran
lipid
transport
includ
cluster
determin
acid
translocas
fabp
pm
plasma
membran
fatti
acid
bind
protein
srbi
scaveng
receptor
bi
may
act
concert
aminopeptidas
n
niemann
pick
dark
circl
believ
play
role
uptak
lipid
digest
product
includ
fatti
acid
fa
cholesterol
ch
sterol
monoglycerid
mg
lysophosphatidylcholin
lpc
intestin
lumen
enterocyt
lipid
digest
product
may
also
efflux
enterocyt
back
intestin
lumen
abc
atpbind
cassett
efflux
transport
black
triangl
transport
across
enterocyt
cytoplasm
thought
facilit
intracellular
lipid
bind
protein
includ
ifabp
intestin
fatti
acid
bind
protein
lfabp
liver
fatti
acid
bind
protein
scp
sterol
carrier
protein
dark
ring
ch
exit
enterocyt
across
basolater
membran
facilit
number
yet
unidentifi
transport
may
facilit
exit
lipid
across
basolater
membran
white
circl
complex
role
less
clear
rel
import
transport
overal
transport
howev
yet
distinguish
protein
mediat
transfer
across
apic
membran
enterocyt
also
demonstr
lysophospholipid
phospholipid
cholesterol
ester
monoglycerid
although
transport
involv
less
well
defin
fa
cholesterol
sever
atpbind
cassett
abc
transport
implic
lipid
uptak
across
plasma
membran
intracellular
lipid
traffick
site
small
intestin
abc
transport
may
therefor
involv
intestin
lipid
absorpt
although
current
role
these
transport
demonstr
exampl
pglycoprotein
believ
influenc
intestin
lipoprotein
format
suggest
pglycoprotein
facilit
absorpt
intracellular
traffick
cholesterol
although
evid
still
circumstanti
addit
appear
facilit
exsorpt
cholesterol
across
basolater
membran
enterocyt
plasma
enhanc
format
nascent
hdl
thought
reduc
excess
intestin
cholesterol
sterol
absorpt
facilit
efflux
enterocyt
recent
evid
also
document
intact
transfer
macromolecular
lipid
complex
lipoprotein
fatti
acid
bound
albumin
across
plasma
membran
hepatocyt
adipocyt
endotheli
cell
line
incorpor
vesicl
deriv
plasma
membran
via
clathrinor
caveolaemedi
endocytosi
endocytosi
may
play
role
uptak
dietari
lipid
small
intestin
form
mix
micellar
vesicular
speci
follow
absorpt
lipid
digest
product
fa
ch
mg
lpc
appear
cross
enterocyt
cytoplasm
passiv
diffus
cytoplasm
diffus
intracellular
solubilis
lipid
facilit
associ
intracellular
lipid
bind
protein
ilbp
includ
intestin
liver
fatti
acid
bind
protein
ifabp
lfabp
respect
sterol
carrier
protein
scp
retinol
retino
acid
bind
protein
ileal
bile
acid
bind
protein
ibabp
increas
albeit
limit
evid
membraneresid
lipid
transport
intracellular
lipid
bind
protein
ilbp
may
impact
uptak
intracellular
disposit
traffick
drug
molecul
may
occur
either
indirectli
via
chang
pattern
intracellular
traffick
disposit
lipid
turn
alter
patter
drug
associ
intracellular
lipid
pool
via
direct
drug
interact
lipid
transport
ilbp
exampl
structur
studi
demonstr
ifabp
lfabp
bind
rel
high
affin
certain
drug
particular
structur
similar
endogen
ligand
fa
drug
bind
ifabp
addit
shown
enhanc
transport
lipophil
drug
molecul
across
model
artifici
membran
degre
transport
enhanc
relat
drug
lipophil
ifabp
bind
affin
recent
studi
also
demonstr
correl
level
express
ifabp
lfabp
mrna
small
intestin
epitheli
cell
rate
transport
lipid
model
drug
halofantrin
intestin
lymph
result
suggest
ifabp
lfabp
may
influenc
lymphat
drug
transport
although
data
requir
confirm
causal
relationship
fabp
level
lymphat
drug
transport
also
unclear
whether
fabp
influenc
lymphat
drug
transport
directli
bind
facilit
drug
transport
indirectli
facilit
lymphat
lipid
transport
interestingli
lfabp
lesser
extent
ifabp
recent
shown
initi
er
bud
prechylomicron
vesicl
transport
lipid
er
golgi
primari
rate
limit
step
lipid
transport
lymph
lfabp
ifabp
may
therefor
broader
influenti
role
lymphat
lipid
transport
previous
suspect
level
ifabp
lfabp
mrna
may
upregul
acut
administr
rel
small
quantiti
lipid
time
cours
h
potenti
relev
absorpt
lipidbas
drug
formul
particularli
multipl
chronic
dose
situat
acut
data
consist
previou
studi
demonstr
transcript
upregul
ifabp
lfabp
follow
chronic
ingest
high
fat
diet
rat
mice
interestingli
regulatori
protein
eg
peroxisom
prolifer
activ
receptor
ppar
influenc
fabp
transcript
express
respons
lipid
ingest
influenc
transcript
express
number
protein
implic
intestin
lipid
absorpt
fabp
may
therefor
one
number
coordin
regul
protein
involv
acut
intestin
respons
lipid
ingest
turn
influenc
rate
extent
intestin
lymphat
lipid
drug
transport
clearli
significantli
data
requir
confirm
refut
suggest
pathway
dictat
intestin
uptak
resynthesi
lipid
digest
product
subsequ
access
lipid
system
circul
via
either
intestin
lymphat
system
portal
vein
blood
describ
fig
essenti
follow
uptak
enterocyt
lipid
digest
product
either
diffus
across
cell
enter
portal
vein
capillari
directli
traffick
endoplasm
reticulum
er
resynthesis
tg
pl
ce
tg
resynthesi
occur
via
pathway
pathway
locat
smooth
endoplasm
reticulum
ser
phosphat
pathway
locat
rough
endoplasm
reticulum
rer
comparison
lpc
resynthesis
pc
lysophospholipid
acylcoa
acyltransferas
ser
proport
lpc
also
hydrolys
form
transport
via
portal
vein
liver
ch
absorb
lumin
side
enterocyt
particularli
fed
state
esterifi
ce
acylcoa
cholesteroloacyltransferas
preferenti
incorpor
lipoprotein
absorpt
intestin
lymph
fast
state
littl
ch
transport
lymph
enter
free
ch
pool
within
enterocyt
contribut
pathway
intestin
tg
resynthesi
larg
part
dictat
sourc
lipid
present
thu
pathway
primari
pathway
tg
synthesi
exogen
avail
eg
follow
ingest
tg
diglycerid
dg
contrast
absenc
exogen
glycerid
eg
fast
state
follow
administr
fa
rather
glycerid
pathway
major
pathway
tg
synthesi
major
portion
tg
form
via
pathway
cross
ser
membran
enter
lipoprotein
assembl
pathway
lipid
enter
lipoprotein
assembl
pathway
within
enterocyt
resid
within
er
golgi
destin
transport
enterocyt
via
intestin
lymph
refer
resid
lymph
lipid
precursor
pool
chylomicron
precursor
pool
sinc
major
lipid
enter
lymph
lipid
precursor
pool
form
via
pathway
composit
lymph
lipid
precursor
pool
consist
primarili
endogen
lipid
fast
state
increasingli
reflect
exogen
lipid
follow
ingest
lipid
addit
tg
form
via
pathway
rel
minor
fraction
tg
produc
via
pathway
also
incorpor
lipoprotein
howev
major
tg
synthesis
via
pathway
enter
pool
lipid
droplet
diffus
distribut
throughout
enterocyt
cytoplasm
cytosol
pool
lipid
refer
portal
lipid
precursor
pool
sinc
major
lipid
pool
transport
system
circul
via
portal
vein
endogen
fatti
acid
cm
remnant
intestin
blood
suppli
taken
enterocyt
across
basolater
membran
also
enter
portal
lipid
precursor
pool
portal
lipid
precursor
pool
consist
primarili
basolaterallysourc
endogen
lipid
intestin
blood
suppli
also
endogen
lipid
synthesis
via
pathway
sinc
portal
lipid
precursor
pool
locat
cytoplasm
surround
membran
lipid
portal
lipid
precursor
pool
may
hydrolys
cytosol
lipas
hydrolys
lipid
may
transport
portal
vein
resynthesis
via
pathway
also
incorpor
lipoprotein
assembl
pathway
lymph
lipid
precursor
pool
aspect
lipoprotein
assembl
occur
within
ser
rer
enterocyt
first
step
sequenti
assembl
fig
intracellular
process
lipid
enterocyt
follow
uptak
across
apic
membran
enterocyt
product
gastrointestin
gi
lumen
lipid
digest
eg
monoglycerid
mg
fatti
acid
fa
may
either
diffus
across
enterocyt
enter
portal
vein
blood
resynthesis
triglycerid
via
either
pathway
associ
smooth
endoplasm
reticulum
ser
phosphat
pathway
associ
rough
endoplasm
reticulum
rer
triglycerid
form
via
pathway
may
enter
endoplasm
reticular
lumen
triglycerid
assembl
lipoprotein
lp
repres
circl
lp
transport
golgi
exocytos
enterocyt
taken
intestin
lymphat
system
sinc
lipid
contain
within
lipoprotein
assembl
pathway
golgi
destin
transport
system
circul
via
intestin
lymphat
system
pool
lipid
refer
lymph
lipid
precursor
pool
dash
blue
line
cytosol
pool
lipid
also
locat
within
enterocyt
lipid
pool
compris
excess
triglycerid
form
via
pathway
endogen
lipid
taken
intestin
blood
suppli
form
either
fa
chylomicron
remnant
cytosol
lipid
subject
hydrolysi
cytosol
lipas
digest
product
form
may
recircul
tg
assembl
pathway
howev
major
lipid
pool
exit
enterocyt
form
tg
free
fa
taken
portal
vein
blood
pool
lipid
transport
enterocyt
via
portal
vein
therefor
refer
portal
lipid
precursor
pool
dash
red
line
figur
modifi
refer
lipoprotein
involv
format
primordi
lipoprotein
within
rer
initi
cotransl
integr
apoprotein
found
surfac
intestin
lipoprotein
believ
essenti
format
intestin
lipoprotein
rer
membran
follow
facilit
associ
phospholipid
mediat
microsom
triglycerid
transport
protein
mtp
lipid
primordi
lipoprotein
releas
rer
lumen
second
step
sequenti
assembl
lipoprotein
involv
format
tg
droplet
within
ser
tg
synthesis
surfac
ser
via
pathway
believ
enter
ser
membran
via
process
facilit
mtp
satur
ser
membran
tg
occur
rel
rapidli
tg
form
small
len
within
ser
membran
eventu
pinch
membran
form
tg
droplet
lumin
side
ser
size
tg
droplet
form
within
ser
thu
subsequ
size
assembl
lipoprotein
believ
depend
mass
type
administ
lipid
final
step
lipoprotein
assembl
involv
fusion
tg
droplet
ser
deriv
primordi
lipoprotein
rer
deriv
junction
ser
rer
lead
format
nascent
lipoprotein
nascent
lipoprotein
subsequ
transport
associ
prechylomicron
transport
vesicl
pctv
golgi
apparatu
golgi
basolater
membran
golgi
deriv
vesicl
contain
multipl
lipoprotein
vesicl
fuse
basolater
membran
enterocyt
lipoprotein
discharg
intercellular
space
underli
enterocyt
free
diffus
connect
tissu
lamina
propria
lymphat
capillari
size
densiti
therefor
type
lipoprotein
eg
low
densiti
lipoprotein
vldl
chylomicron
cm
form
intestin
thu
larg
depend
mass
type
lipid
ingest
fast
state
follow
administr
pl
tg
droplet
form
within
lymph
lipid
precursor
pool
rel
small
lead
format
vldl
diamet
nm
sediment
coeffici
f
b
densiti
b
gml
compris
primarili
endogen
lipid
resynthesis
triglycerid
via
pathway
contrast
postprandi
state
administr
exogen
lipid
tg
droplet
form
within
lymph
lipid
precursor
pool
larger
lead
progress
format
secret
rel
larg
exogen
lipid
enrich
cm
diamet
nm
f
b
gml
addit
vldl
lymph
whilst
lymphat
lipid
transport
lipoprotein
format
increas
substanti
follow
fatti
meal
even
fast
state
endogen
lipid
flux
intestin
mesenter
lymph
maintain
exampl
intestin
vldl
assembl
endogen
lipid
sourc
contribut
approxim
total
fast
plasma
tg
endogen
lipid
may
enter
enterocyt
across
apic
lumin
basolater
membran
apicallysourc
endogen
lipid
includ
bile
desquam
enterocyt
basolaterallysourc
endogen
lipid
includ
fatti
acid
cm
remnant
taken
intestin
blood
suppli
cm
remnant
uptak
mediat
apo
receptor
basolater
membran
endogen
lipid
may
also
synthesis
de
novo
enterocyt
potenti
sourc
endogen
lipid
apicallysourc
biliari
deriv
lipid
major
contributor
lymphat
lipid
transport
fast
state
rat
bile
divers
substanti
reduc
fast
lymphat
lipid
transport
cell
desquam
provid
minor
sourc
apicallyderiv
materi
contribut
de
novo
lipid
synthesi
enterocyt
thought
even
lower
basolaterallysourc
endogen
lipid
intestin
blood
thought
predominantli
suppli
cytosol
portal
lipid
precursor
pool
although
portal
lipid
precursor
pool
lipid
may
redirect
lymph
lipid
precursor
pool
via
hydrolysi
resynthesi
bilederiv
pl
also
thought
requir
format
lipidrich
cm
lipoprotein
appear
enhanc
endogen
exogen
lipid
transport
lymph
abil
pl
enhanc
lymphat
transport
elegantli
demonstr
studi
use
mice
biliari
phosphatidylcholin
secret
deplet
normal
biliari
bs
secret
remain
anim
postprandi
format
cm
occur
histor
larg
mass
exogen
lipid
assum
requir
stimul
suffici
lymphat
lipid
flux
lipoprotein
format
support
appreci
lymphat
drug
transport
khoo
et
al
howev
shown
greyhound
dog
signific
fast
state
lymphat
drug
transport
possibl
follow
drug
administr
singl
unit
capsul
contain
long
chain
lc
lipidbas
formul
extent
lymphat
drug
transport
dose
model
highli
lipophil
antimalari
halofantrin
hf
support
singl
unit
capsul
formul
lc
lipid
substanti
greater
recov
lymph
administr
lipid
free
formul
hf
fast
state
less
recov
lymph
dose
follow
lipid
meal
interestingli
follow
administr
lc
lipid
formul
mass
tg
recov
lymph
g
h
greater
combin
endogen
tg
transport
lymph
fast
state
g
h
mass
exogen
lipid
dose
g
suggest
administr
lc
lipid
formul
led
recruit
endogen
lipid
transport
lymph
rel
high
extent
lymphat
drug
transport
therefor
appear
support
recruit
endogen
lymph
lipid
stimul
endogen
lymphat
transport
consist
previou
studi
rat
continu
infus
increas
quantiti
mgh
mgh
oleic
acid
period
h
shown
increas
endogen
exogen
lipid
transport
intestin
lymph
dose
depend
manner
recent
experi
lymphcannul
bileduct
cannul
rat
examin
role
endogen
fatti
acid
recruit
lymphat
drug
transport
studi
rat
administ
seri
lipid
formul
contain
halofantrin
hf
model
drug
either
mg
mg
oleic
acid
oa
h
effect
addit
mm
bile
salt
bs
sodium
taurochol
lysophosphatidylcholin
lpc
also
examin
administr
mg
oa
increas
endogen
exogen
lipid
transport
lymph
compar
administr
either
normal
salin
mg
oa
subsequ
enhanc
lymphat
drug
transport
contrast
administr
smaller
lipid
dose
mg
oa
stimul
endogen
lymphat
lipid
transport
baselin
suggest
endogen
lipid
recruit
lipid
dose
depend
interestingli
addit
mm
bs
mg
oa
formul
rat
enhanc
endogen
lymphat
lipid
output
lymphat
transport
hf
dose
parallel
stimul
increas
biliari
lipid
secret
data
therefor
suggest
bs
infus
stimul
biliari
lipid
secret
turn
support
enhanc
lymphat
drug
transport
contrast
whilst
addit
lpc
mg
oa
dispers
bs
solut
substanti
enhanc
endogen
lipid
transport
lymph
biliari
lipid
output
lymphat
drug
transport
increas
obtain
administr
mg
oab
formul
alon
lumin
lpc
therefor
appear
recruit
endogen
lipid
lymph
nonbiliari
deriv
sourc
possibl
via
uptak
lipid
intestin
blood
suppli
across
enterocyt
basolater
membran
basolater
deriv
lipid
less
abl
support
lymphat
drug
transport
compar
biliari
deriv
lipid
see
fig
describ
section
two
mucos
pool
lipid
within
intestin
absorpt
cell
portal
lipid
precursor
pool
consist
number
discret
lipid
droplet
distribut
throughout
enterocyt
cytoplasm
lipid
pool
predominantli
transport
system
circul
via
portal
vein
contrast
lymph
lipid
precursor
pool
consist
lipid
droplet
destin
transport
system
circul
via
intestin
lymphat
system
encompass
lipid
within
lipoprotein
assembl
pathway
er
golgi
due
close
relationship
sourc
lipid
synthet
pathway
involv
format
portal
lymph
lipid
precursor
pool
see
section
size
two
pool
interrel
thu
fast
state
rel
small
amount
lipid
found
lipid
pool
wherea
administr
exogen
lipid
size
turnov
rate
lipid
pool
may
chang
significantli
exampl
infus
triolein
anaesthetis
rat
total
mass
lipid
contain
lymph
portal
lipid
pool
increas
amount
lipid
portal
lipid
precursor
pool
increas
compar
fast
state
interestingli
addit
phosphatidylcholin
infus
reduc
mass
lipid
portal
lipid
precursor
pool
redirect
lipid
lymph
lipid
precursor
pool
turn
led
signific
increas
lymphat
lipid
output
parallel
increas
lipid
lymph
lipid
precursor
pool
suggest
size
portal
lipid
precursor
pool
invers
relat
effici
lymphat
lipid
output
due
like
high
affin
lymphat
transport
drug
intracellular
lipid
domain
recent
initi
seri
studi
examin
potenti
impact
chang
size
turnov
kinet
mucos
lipid
pool
intracellular
disposit
lymphat
transport
lipophil
drug
steadi
state
lymphcannul
rat
model
employ
base
model
use
previous
lipid
fig
schemat
represent
propos
mechan
differ
sourc
endogen
lipid
support
lymphat
drug
transport
administr
exogen
fatti
acid
fa
appear
lead
recruit
endogen
fa
intestin
lymph
endogen
fa
may
enter
enterocyt
across
apic
lumin
membran
eg
fa
deriv
lipid
secret
bile
basolater
membran
eg
fa
intestin
blood
suppli
howev
apicallyand
basolaterallysourc
lipid
traffick
pool
lipid
within
enterocyt
subsequ
enter
lymph
differ
manner
thu
basolaterallysourc
endogen
lipid
appear
larg
enter
portal
lipid
precursor
pool
major
transport
enterocyt
system
circul
via
portal
vein
proport
lipid
portal
lipid
precursor
pool
also
redirect
lymph
lipid
precursor
pool
subsequ
enter
lymph
lipid
howev
appear
support
drug
transport
lymph
contrast
apicallysourc
lipid
either
endogen
exogen
traffick
directli
lymph
lipid
precursor
pool
support
drug
uptak
lymph
lipid
precursor
pool
transport
lymph
biochemistri
literatur
best
knowledg
howev
first
time
techniqu
appli
studi
lymphat
drug
transport
seri
lipidbas
drug
formul
contain
radiolabel
fatti
acid
fa
hf
model
drug
administ
continu
intraduoden
infus
lymphcannul
rat
steadi
state
rate
fa
drug
transport
lymph
achiev
steadi
state
achiev
radiolabel
fa
drug
formul
compon
remov
infus
allow
assess
washout
profil
fa
drug
transport
lymph
first
order
rate
constant
describ
fa
drug
transport
lymph
lipid
precursor
pool
lymph
determin
washout
profil
mass
fa
drug
lymph
lipid
precursor
pool
subsequ
calcul
rate
transport
fa
drug
lymph
rate
constant
washout
profil
sourc
endogen
fa
lipid
pool
also
probe
compar
endogen
lipid
output
bile
bileduct
cannul
rat
rate
endogen
lymphat
lipid
flux
anim
administ
formul
follow
continu
administr
low
lipid
dose
formul
contain
long
chain
length
fa
mg
oleic
acid
fa
h
steadi
state
lymph
lipid
precursor
pool
lymph
contain
primarili
endogen
fa
rather
exogen
fa
consist
previou
result
mass
drug
solubilis
lymph
lipid
precursor
pool
follow
administr
small
lipid
dose
relat
total
mass
lipid
lymph
lipid
precursor
pool
rather
appear
depend
mass
biliari
deriv
endogen
fa
sourc
endogen
fa
lymph
lipid
pool
contrast
exogen
fa
major
lipid
sourc
lymph
lipid
pool
lymph
follow
administr
higher
lipid
dose
formul
mg
fah
exogen
fa
primari
driver
lymphat
drug
transport
mass
drug
lymph
lipid
precursor
pool
avail
lymphat
transport
proport
mass
total
endogen
plu
exogen
fa
lipid
pool
follow
administr
higher
lipid
dose
formul
increas
mass
endogen
exogen
fa
lymph
lipid
precursor
pool
eg
follow
increas
lipid
dose
addit
bs
lpc
formul
accompani
increas
rate
fa
transport
lymph
steadi
state
howev
rate
lymphat
fa
transport
increas
direct
proport
increas
size
lymph
lipid
pool
sinc
rate
fa
transport
lymph
product
mass
fa
lymph
lipid
pool
rate
constant
describ
turnov
fa
pool
lymph
greater
fraction
increas
mass
lipid
pool
rel
rate
transport
lymph
indic
decreas
magnitud
turnov
rate
constant
pool
expand
suggest
fa
turnov
lymph
lipid
precursor
pool
lymph
may
finit
capac
satur
lymph
lipid
pool
expand
consist
previou
studi
suggest
lipid
transport
enterocyt
lymph
may
limit
rate
transport
vesicl
carri
prematur
lipoprotein
er
golgi
bud
er
membran
increas
mass
drug
lymph
lipid
precursor
pool
similarli
accompani
increas
steadi
state
rate
drug
transport
lymph
howev
unlik
data
fa
first
order
turnov
rate
constant
describ
drug
transport
lymph
lipid
pool
lymph
rel
constant
regardless
mass
lipid
administ
size
lymph
lipid
pool
furthermor
case
rate
constant
describ
drug
turnov
lower
correspond
rate
constant
lipid
given
drug
thought
transport
lymph
lipid
precursor
pool
lymph
conjunct
lipid
ie
associ
lymph
lipoprotein
data
unexpect
suggest
possibl
drug
remov
lymph
lipid
pool
occur
via
transfer
lymph
also
via
addit
rate
process
henc
lower
expect
lymph
transport
rate
constant
subsequ
studi
suggest
addit
process
enterocytebas
metabol
impact
lipoprotein
associ
enterocytebas
metabol
describ
detail
section
result
studi
therefor
demonstr
rate
extent
lymphat
drug
transport
depend
size
turnov
kinet
lymph
lipid
precursor
pool
formul
excipi
expand
lymph
lipid
precursor
pool
phospholipid
may
enhanc
lymphat
drug
transport
whilst
earli
research
suggest
rel
small
lipid
dose
size
relev
develop
lipidbas
formul
may
alter
intracellular
pool
lipid
therebi
impact
intracellular
drug
disposit
research
requir
defin
care
chang
impact
lymphport
drug
partit
well
overal
absorpt
bioavail
lipophil
drug
lymphat
drug
transport
firstpass
metabol
hepat
firstpass
metabol
impact
lymphat
drug
transport
hepat
firstpass
metabol
well
describ
literatur
briefli
howev
lymphat
transport
drug
protect
firstpass
hepat
metabol
mesenter
lymph
unlik
portal
blood
empti
directli
system
circul
without
first
pass
liver
exampl
testosteron
extrem
limit
oral
bioavail
due
extens
presystem
clearanc
intestin
liver
contrast
testosteron
undecano
tu
highli
lipophil
prodrug
oral
bioavail
exhibit
androgen
activ
oral
administr
androgen
activ
oral
administ
tu
gener
attribut
system
activ
metabolit
dht
form
tu
entri
system
circul
via
intestin
lymph
import
lymphat
transport
tu
system
exposur
examin
greyhound
dog
follow
postprandi
administr
tu
system
avail
found
result
system
hydrolysi
lymphat
transport
tu
system
exposur
human
also
increas
substanti
follow
oral
tu
administr
fed
state
compar
administr
fast
state
increas
postprandi
exposur
therefor
like
reflect
enhanc
lymphat
transport
tu
increas
lumin
solubilis
poorli
water
solubl
steroid
addit
hepat
firstpass
metabol
enterocytebas
drug
metabol
may
also
influenc
drug
associ
lymph
lipoprotein
exampl
vetter
et
al
examin
impact
enterocytebas
metabol
lymphat
transport
benzo
pyren
bp
follow
oral
deliveri
killifish
oral
administr
bp
lipid
dispers
si
lumen
cotransport
across
microvillu
membran
accumul
togeth
within
enterocyt
eventu
howev
lipid
transport
intestin
lymph
form
lipoprotein
wherea
bp
dispers
throughout
cell
becom
associ
lipid
author
suggest
bp
convert
hydrophil
metabolit
contact
metabol
enzym
situat
ser
therefor
bp
absorb
system
circul
metabolit
via
portal
vein
studi
indic
format
larger
fat
droplet
within
enterocyt
follow
fatti
meal
reduc
transfer
bp
lipid
droplet
associ
ser
membran
microsom
enzym
therebi
reduc
bp
metabol
describ
section
data
obtain
laboratori
use
steadi
state
lymphcannul
rat
model
also
suggest
drug
associ
lymph
lipoprotein
lymph
lipid
pool
may
alter
pattern
drug
metabol
enterocyt
studi
first
order
rate
constant
describ
hf
transport
lymph
lipid
precursor
pool
lymph
significantli
lower
equival
rate
constant
describ
fa
turnov
follow
administr
seri
lipid
formul
anaesthetis
rat
tabl
differ
rate
constant
initi
suggest
diverg
two
transport
process
lipid
vs
drug
content
seemingli
odd
like
cotransport
druglipoprotein
complex
lymph
altern
explan
howev
lie
possibl
remov
hf
lymph
lipid
pool
occur
transport
lymph
also
addit
first
order
metabol
process
consist
suggest
hf
suscept
firstpass
metabol
desbutylhalofantrin
hfm
enzym
also
present
enterocyt
howev
contribut
enterocytebas
hepat
firstpass
metabol
overal
metabol
profil
hf
examin
previous
subsequ
studi
therefor
probe
basi
differ
first
order
rate
constant
describ
hf
fa
transport
lymph
administ
hf
without
predos
inhibitor
ketoconazol
kc
also
via
substitut
hf
essenti
nonmetabolis
probe
ddt
data
confirm
first
order
rate
constant
drug
fa
turnov
lymph
significantli
differ
administr
either
hf
presenc
kc
ddt
support
suggest
hf
remov
lymph
lipid
precursor
pool
enterocytebas
metabol
data
allow
examin
relationship
enterocytebas
metabol
lymphat
drug
transport
use
differ
first
order
rate
constant
obtain
hf
fa
transport
lymph
indirect
indic
enterocytebas
metabol
reexamin
data
tabl
therefor
suggest
coadministr
hf
larger
lipid
load
mg
mg
lpc
per
h
compar
mg
oa
per
h
increas
size
lymph
lipid
precursor
pool
increas
extent
hf
lymphat
transport
also
reduc
differ
first
order
rate
constant
hf
fa
turnov
lymph
suggest
reduct
rate
enterocytebas
metabol
hf
presenc
larger
lymph
lipid
precursor
pool
mechan
coadministr
increas
quantiti
lipid
reduc
enterocytebas
metabol
studi
may
reflect
sequestr
drug
larger
lipid
droplet
form
ser
higher
lipid
dose
turn
reduc
drug
access
metabol
enzym
locat
ser
surfac
previou
studi
shown
plasma
ratio
hf
metabolit
hfm
hf
lower
follow
administr
hf
fatti
meal
suggest
least
part
due
avoid
firstpass
hepat
metabol
stimul
lymphat
transport
hf
recent
data
suggest
stimul
lymphat
transport
hf
via
coadministr
lipid
may
enhanc
bioavail
avoid
enterocytebas
hepat
firstpass
metabol
tabl
total
mass
fatti
acid
fa
lymph
lipid
precursor
pool
first
order
rate
constant
describ
fa
k
x
drug
k
transport
lymph
lipid
precursor
pool
lymph
h
fraction
differ
first
order
rate
constant
describ
fa
drug
transport
lymph
lipid
precursor
pool
lymph
kx
follow
continu
intraduoden
infus
lipid
formul
contain
dose
either
halofantrin
hf
ddt
mgh
oleic
acid
oa
mgh
oa
mgh
lysophosphatidylcholin
lpc
dispers
mm
bile
salt
solut
mesenter
lymph
duct
cannul
rat
n
mean
sem
b
statist
differ
k
x
follow
administr
formul
p
b
c
statist
differ
k
follow
administr
formul
contain
ddt
p
b
statist
differ
compar
kx
follow
administr
formul
hf
p
b
identif
increasingli
lipophil
drug
candid
dictat
recent
increas
interest
mechan
drug
access
lymph
formul
approach
may
taken
maximis
minimis
lymphat
transport
potenti
impact
lymphat
transport
drug
process
within
enterocyt
liver
stimul
intestin
lymphat
transport
potenti
advantag
includ
reduct
firstpass
metabol
deliveri
high
concentr
drug
lymphat
system
whilst
recent
studi
increas
understand
role
lipid
precursor
pool
lymphat
drug
transport
start
probe
import
sourc
endogen
lipid
might
support
lymphat
drug
transport
level
mechanist
understand
drug
access
lymph
cellular
level
remain
rel
poor
increas
use
applic
intestin
lymph
altern
mode
transport
system
circul
therefor
depend
studi
address
fundament
mechan
drug
associ
lipoprotein
enterocyt
impact
lipid
formul
excipi
process
